Told You So....
Protein Design Labs' announcement that it would discontinue trials of its antibody Zenapax against psoriasis was no surprise to SG Cowen analyst Bill Tanner, who'd reported at the end of February that clinicians involved in testing weren't very enthusiastic about it. Tanner may have been bloodied by criticism that his report was based on data that could not be statistically significant--but he remained unbowed. PDL's news reaffirmed his belief that analysts need to do fundamental research and talk to clinicians, instead of simply believing everything a company says.
You may also be interested in...
Just five weeks before the US election, a Medtech Insight analysis shows medical device companies are spending more on Democrat Joe Biden’s campaign than on Republican Donald Trump’s.
Denmark’s Orphazyme has raised more funds to market its lead product, the heat shock protein amplifier, arimoclomol, in the US and Europe, and to evaluate the compound for other lysosomal storage and neurodegenerative disorders.
Pacific Biosciences of California and Aziyo Biologics both acquire new finance chiefs; Illumina hires a new chief marketing officer; WishBone Medical president moves over to take helm at Electromedical Products International; and more.